Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study

BACKGROUND: Limited prospective data are available on the long-term safety of darbepoetin alfa (DA) for treating anemia in children with chronic kidney disease (CKD). METHODS: In this prospective, phase IV, observational registry study, children ≤16 years of age with CKD anemia and receiving DA were...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Nephrol
Autors principals: Schaefer, Franz, Hoppe, Bernd, Jungraithmayr, Therese, Klaus, Günter, Pape, Lars, Farouk, Mourad, Addison, Janet, Manamley, Nick, Vondrak, Karel
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4756039/
https://ncbi.nlm.nih.gov/pubmed/26482252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-015-3225-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars